180 related articles for article (PubMed ID: 19183836)
1. Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.
Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
J Bone Miner Metab; 2009; 27(2):168-74. PubMed ID: 19183836
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of risedronate in Japanese male patients with primary osteoporosis.
Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
Intern Med; 2008; 47(8):717-23. PubMed ID: 18421187
[TBL] [Abstract][Full Text] [Related]
3. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
Ringe JD; Farahmand P; Faber H; Dorst A
Rheumatol Int; 2009 Jan; 29(3):311-5. PubMed ID: 18762944
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
Ringe JD; Faber H; Farahmand P; Dorst A
Rheumatol Int; 2006 Mar; 26(5):427-31. PubMed ID: 16001181
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Yonsei Med J; 2009 Aug; 50(4):474-81. PubMed ID: 19718394
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
Hagino H; Kishimoto H; Ohishi H; Horii S; Nakamura T
Bone; 2014 Feb; 59():44-52. PubMed ID: 24184313
[TBL] [Abstract][Full Text] [Related]
7. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
Bradbury LA; Barlow S; Geoghegan F; Hannon RA; Stuckey SL; Wass JA; Russell RG; Brown MA; Duncan EL
Osteoporos Int; 2012 Jan; 23(1):285-94. PubMed ID: 21739105
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study.
Leung JY; Ho AY; Ip TP; Lee G; Kung AW
Bone; 2005 Feb; 36(2):358-64. PubMed ID: 15780963
[TBL] [Abstract][Full Text] [Related]
9. Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study.
Takakuwa M; Iwamoto J; Konishi M; Zhou Q; Itabashi K
J Bone Miner Metab; 2011 Jan; 29(1):88-95. PubMed ID: 20533068
[TBL] [Abstract][Full Text] [Related]
10. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
[TBL] [Abstract][Full Text] [Related]
11. Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.
Takakuwa M; Iwamoto J; Itabashi K
Clin Drug Investig; 2012 Feb; 32(2):121-9. PubMed ID: 22185631
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.
Majima T; Komatsu Y; Doi K; Takagi C; Shigemoto M; Fukao A; Morimoto T; Corners J; Nakao K
J Bone Miner Metab; 2006; 24(2):105-13. PubMed ID: 16502116
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
15. Effect of stopping risedronate after long-term treatment on bone turnover.
Eastell R; Hannon RA; Wenderoth D; Rodriguez-Moreno J; Sawicki A
J Clin Endocrinol Metab; 2011 Nov; 96(11):3367-73. PubMed ID: 21865359
[TBL] [Abstract][Full Text] [Related]
16. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Hadji P; Zanchetta JR; Russo L; Recknor CP; Saag KG; McKiernan FE; Silverman SL; Alam J; Burge RT; Krege JH; Lakshmanan MC; Masica DN; Mitlak BH; Stock JL
Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
[TBL] [Abstract][Full Text] [Related]
17. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
[TBL] [Abstract][Full Text] [Related]
18. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Sestak I; Singh S; Cuzick J; Blake GM; Patel R; Gossiel F; Coleman R; Dowsett M; Forbes JF; Howell A; Eastell R
Lancet Oncol; 2014 Dec; 15(13):1460-1468. PubMed ID: 25456365
[TBL] [Abstract][Full Text] [Related]
19. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
Kanaji A; Higashi M; Namisato M; Nishio M; Ando K; Yamada H
Lepr Rev; 2006 Jun; 77(2):147-53. PubMed ID: 16895071
[TBL] [Abstract][Full Text] [Related]
20. Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice.
Soen S; Umemura T; Ando T; Kamisaki T; Nishikawa M; Muraoka R; Ikeda Y; Takeda K; Osawa M; Nakamura T
J Bone Miner Metab; 2017 Jul; 35(4):419-427. PubMed ID: 27565972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
